Trials / Terminated
TerminatedNCT03185559
A Randomized, Double-blind Clinical Investigation to Evaluate the Use of the Relievion™ Device in Treating Migraine.
A Prospective, Randomized, Double-blind, Parallel-group, Sham Controlled Single-center Pivotal Clinical Investigation to Evaluate the Clinical Safety and Performance of Self-administered Home-use Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation Device (Relievion™) in Treating Migraine.
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Neurolief Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the clinical performance and safety of a self-administered abortive treatment for migraine headache using combined occipital and supraorbital transcutaneous nerve stimulator (Neurolief device, Relievion™).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Relievion Device- Treatment Stimulation | 1 Hour self-administered treatment specific occipital and supraorbital transcutaneous nerve stimulation |
| DEVICE | Relievion Device- Sham stimulation | 1 Hour self-administered sham occipital and supraorbital transcutaneous nerve stimulation |
Timeline
- Start date
- 2017-07-23
- Primary completion
- 2018-01-09
- Completion
- 2018-01-09
- First posted
- 2017-06-14
- Last updated
- 2018-03-29
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT03185559. Inclusion in this directory is not an endorsement.